4:03 PM ET
10-Q
Financial Results
Oruka Therapeutics Q3 2026 Results: Net Loss of $50M, Loss Widens
Oruka Therapeutics reported a net loss of $123.0 million for the nine months ended September 30, 2026, driven by $126.1 million in research and development expenses. The company significantly strengthened its balance sheet during the period, ending with $1.23 billion in total assets following a major common stock offering in April 2026 and ATM program activity.
- Key figure
- Net loss $50M